TAP1 and cancer: Our results revealed aberrant expression of TAP1 in the majority of pan-cancer types, and that this expression is significantly correlated with clinical prognosis, immune cell infiltration, expression of ICPs, TME biomarkers, and immunotherapy efficacy.